

Special Issue

Liposome-Mediated Natural Compounds in Cancer Therapy

Message from the Guest Editors

Cancer remains one of the leading causes of death worldwide. Chemotherapy is associated with poor selectivity, systemic toxicity, and drug resistance. In recent years, there has been growing interest in exploiting the potential of natural compounds derived from plants, fungi, and other sources for cancer therapy. These bioactive compounds often exhibit remarkable anti-cancer properties. However, challenges related to their low bioavailability, instability, and non-specific distribution have hindered their widespread clinical application.

Liposome-based drug delivery systems are a promising solution to these challenges as they offer increased biocompatibility, improved solubility for poorly water-soluble compounds, and the potential for targeted delivery to tumor sites. By encapsulating natural compounds in liposomes, it is possible to enhance their stability, bioavailability, and therapeutic efficacy, while reducing their systemic toxicity and side effects. This Special Issue aims to provide a comprehensive overview of the latest advancements in the liposome-dependent delivery of natural compounds, both alone and in combination with chemotherapeutic agents, for cancer therapy.

Guest Editors

Dr. Panayiota Christodoulou

Department of Medicine, School of Medicine, European University
Cyprus, 1516 Nicosia, Cyprus

Dr. Athanasios Skouras

Department of Nursing, Faculty of Health Sciences, Hellenic
Mediterranean University, Heraklion, 71004 Crete, Greece

Deadline for manuscript submissions

31 October 2025



Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



mdpi.com/si/224292

Future Pharmacology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
future-
pharmacology@mdpi.com

[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)





Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Fabrizio Schifano

Psychopharmacology, Drug Misuse and Novel Psychoactive
Substances Research Unit, School of Life and Medical Sciences,
University of Hertfordshire, Hertfordshire AL10 9AB, UK

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), EBSCO, and other
databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy)